0001209191-22-041330.txt : 20220706 0001209191-22-041330.hdr.sgml : 20220706 20220706181828 ACCESSION NUMBER: 0001209191-22-041330 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220705 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brumm Joshua T CENTRAL INDEX KEY: 0001528826 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 221070067 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-05 0 0001818794 Dyne Therapeutics, Inc. DYN 0001528826 Brumm Joshua T C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD WALTHAM MA 02451 1 1 0 0 See Remarks Common Stock 2022-07-05 4 A 0 24118 0.00 A 230902 D Common Stock 2022-07-06 4 D 0 10963 8.24 D 219939 D Stock Option (right to buy) 5.54 2022-07-05 4 A 0 153931 0.00 A 2030-07-30 Common Stock 153931 153931 D Stock Option (right to buy) 19.00 2022-07-05 4 A 0 78386 0.00 A 2030-09-15 Common Stock 78386 78386 D The Performance Restricted Stock Units (PRSUs) were granted on September 17, 2020, with 100% of the PRSUs to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Includes 183,688 unvested RSUs. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of PRSUs granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $8.24 to $8.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. The option was granted on September 16, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Chief Executive Officer and President /s/ Richard Scalzo, Attorney-in-Fact 2022-07-06